Cannabis Abstinence and Neurocognitive Assessment in Adolescence
Recruiting now
Conditions studied: Cannabis Dependence, Harmful Use, Cognitive Assessment
In brief
Cannabis Abstinence and Neurocognitive Assessment in Adolescence
Key facts
- Study ID
- NCT07160153
- Run by
- University Hospital Pilsen
- People needed
- 29
- Starts
- 2024-12-03
- Expected to finish
- 2029-08-31
- Last updated by the study team
- 2025-09-19
Who can join
Age: 15 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.
You may not qualify if…
- psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
- somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
- Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.
Where it is running
- University Hospital Pilsen — Pilsen, Czechia, Czechia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.